Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Nenhuma Miniatura disponível
Data
2014-01-01
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Bentham Science Publ Ltd
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
The treatment of central nervous system (CNS) diseases is a major challenge. The presence of the barrier intended to protect the brain from unwanted molecules also impairs the efficacy of CNS-targeted drugs. The discovery of drug targets for CNS diseases opens a door for the selective treatment of these diseases. However, the physicochemical properties of drugs, including their hydrophilic properties and their peripheral metabolism, as well as the blood-brain barrier, can adversely affect the therapeutic potential of CNS-targeted drugs. Although peptides are often metabolized by enzymes, they are of particular interest for the treatment of CNS diseases or as carriers to deliver drugs to the brain. In this review, we discuss the use of peptides as potential prodrugs for the treatment of CNS diseases.
Descrição
Idioma
Inglês
Como citar
Current Medicinal Chemistry. Sharjah: Bentham Science Publ Ltd, v. 21, n. 23, p. 2599-2609, 2014.
